DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Clinical trials for DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED explained in plain language.
Never miss a new study
Get alerted when new DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED trials appear
Sign up with your email to follow new studies for DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to stop aggressive lymphomas from coming back
Disease control OngoingThis study tests whether adding the drug venetoclax to standard chemotherapy can keep high-grade B-cell lymphomas from returning or getting worse. About 363 adults with these aggressive lymphomas will receive either the usual chemo or the usual chemo plus venetoclax. The goal is …
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 04:17 UTC
-
Engineered donor cells take on Hard-to-Treat lymphomas
Disease control OngoingThis early-phase study tests a new treatment called P-CD19CD20-ALLO1 for people with certain types of B-cell lymphoma that have come back or not responded to standard therapy. The treatment uses donor immune cells that are specially designed to find and attack cancer cells. The m…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE1 • Sponsor: Poseida Therapeutics, Inc. • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
New combo therapy aims to boost CAR T-Cell power against lymphoma
Disease control OngoingThis early-phase study tests whether adding the drug acalabrutinib to CAR T-cell therapy (axicabtagene ciloleucel) is safe and works better for people with certain B-cell lymphomas. About 23 adults whose cancer has not responded to prior treatments will receive the combination. T…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE1, PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 12, 2026 13:40 UTC
-
Could an oral drug boost chemo for seniors with lymphoma?
Disease control OngoingThis study looks at whether adding an oral medication (CC-486, or oral azacitidine) to a standard reduced-dose chemo regimen (R-miniCHOP) can help people aged 75 and older with newly diagnosed aggressive B-cell lymphomas. The goal is to see if the combination improves how long pa…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:53 UTC
-
New combo therapy aims to boost immune attack on tough lymphomas
Disease control OngoingThis phase 2 trial tests whether adding varlilumab to nivolumab helps people with aggressive B-cell lymphomas that have returned or not responded to standard therapy. About 54 participants will receive either nivolumab alone or nivolumab plus varlilumab. The goal is to see if the…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:40 UTC
-
Nanochip could spot lymphoma relapse early
Knowledge-focused OngoingThis study tests a new nanochip technology to see if it can better monitor how well treatment is working and detect if lymphoma comes back in people with diffuse large B-cell lymphoma. About 73 participants will provide blood samples during their standard chemotherapy. The goal i…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: NA • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated May 17, 2026 04:15 UTC